ECSP16096831A - Derivados de naftiridinadiona - Google Patents

Derivados de naftiridinadiona

Info

Publication number
ECSP16096831A
ECSP16096831A ECIEPI201696831A ECPI201696831A ECSP16096831A EC SP16096831 A ECSP16096831 A EC SP16096831A EC IEPI201696831 A ECIEPI201696831 A EC IEPI201696831A EC PI201696831 A ECPI201696831 A EC PI201696831A EC SP16096831 A ECSP16096831 A EC SP16096831A
Authority
EC
Ecuador
Prior art keywords
naphthyridinadiona
derivatives
medicines
substituents
medicine
Prior art date
Application number
ECIEPI201696831A
Other languages
English (en)
Inventor
Schmiedeberg Niko
Spanka Carsten
Reinhardt Juergen
Original Assignee
Productos Familia Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Productos Familia Sa filed Critical Productos Familia Sa
Publication of ECSP16096831A publication Critical patent/ECSP16096831A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

RESUMEN La invención se refiere a un compuesto de la fórmula (I’): (I’) o a una sal del mismo, en donde los sustituyentes son como se definen en la memoria descriptiva; a su preparación, a su uso como un medicamento, y a los medicamentos que lo comprenden.
ECIEPI201696831A 2014-06-03 2016-12-28 Derivados de naftiridinadiona ECSP16096831A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14170976 2014-06-03

Publications (1)

Publication Number Publication Date
ECSP16096831A true ECSP16096831A (es) 2018-04-30

Family

ID=50841689

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201696831A ECSP16096831A (es) 2014-06-03 2016-12-28 Derivados de naftiridinadiona

Country Status (28)

Country Link
US (2) US10138232B2 (es)
EP (1) EP3152209B1 (es)
JP (2) JP6343034B2 (es)
KR (1) KR101905295B1 (es)
CN (1) CN106459043B (es)
AP (1) AP2016009545A0 (es)
AR (1) AR100706A1 (es)
AU (2) AU2015270125B2 (es)
BR (1) BR112016027383A8 (es)
CA (1) CA2950724A1 (es)
CL (1) CL2016003081A1 (es)
CR (1) CR20160565A (es)
CU (1) CU24438B1 (es)
EA (1) EA030374B1 (es)
EC (1) ECSP16096831A (es)
ES (1) ES2731802T3 (es)
GT (1) GT201600252A (es)
IL (1) IL248773B (es)
MX (1) MX374245B (es)
MY (1) MY178379A (es)
PE (1) PE20170086A1 (es)
PH (2) PH12016502293B1 (es)
SG (1) SG11201609209YA (es)
SV (1) SV2016005331A (es)
TN (1) TN2016000490A1 (es)
TW (1) TWI688565B (es)
UY (1) UY36150A (es)
WO (1) WO2015186063A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015186062A1 (en) 2014-06-03 2015-12-10 Novartis Ag PYRIMIDO[4,5-b]QUINOLINE-4,5(3H,10H)-DIONE DERIVATIVES
EP3152207B1 (en) 2014-06-03 2019-05-08 Novartis AG Pyridopyrimidinedione derivatives as suppressors of non-sens mutations
CA2950724A1 (en) 2014-06-03 2015-12-10 Novartis Ag Naphthyridinedione derivatives
WO2019225625A1 (ja) * 2018-05-23 2019-11-28 京都薬品工業株式会社 リードスルー誘導剤およびその医薬用途
KR102719696B1 (ko) 2018-07-24 2024-10-21 소니 세미컨덕터 솔루션즈 가부시키가이샤 반도체 장치
KR20240070637A (ko) * 2021-09-30 2024-05-21 캐러웨이 테라퓨틱스, 인크. Trpml의 조정제, 그의 조성물 및 사용 방법
WO2024161623A1 (ja) * 2023-02-03 2024-08-08 株式会社 RINAT Imaging リードスルー薬、リードスルー用組み合わせ剤及び核酸プローブの使用
CN117756607A (zh) * 2023-12-01 2024-03-26 陕西煤业化工技术研究院有限责任公司 一种二甲酚馏分异构化生产高值二甲酚的工艺及系统

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2884170B2 (ja) 1989-08-24 1999-04-19 株式会社フジモト・ブラザーズ ５−デアザフラビン系化合物を有効成分とする制癌剤
JP2989871B2 (ja) * 1989-08-30 1999-12-13 大日本製薬株式会社 三環式化合物
DE4035479A1 (de) 1990-11-08 1992-05-14 Basf Ag Substituierte pyrido (2,3-d)pyrimidin-2,4(1h,3h)-dione
WO1996028444A1 (en) 1995-03-15 1996-09-19 Pfizer Inc. 5,10-DIHYDROPYRIMIDO[4,5-b]QUINOLIN-4(1H)-ONE TYROSINE KINASE INHIBITORS
US6016875A (en) * 1998-02-10 2000-01-25 Case Corporation Gain adaptation control for hydraulic systems
US6468990B1 (en) 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2004006906A2 (en) 2002-07-15 2004-01-22 Combinatorx, Incorporated Methods for the treatment of neoplasms
EP4101846B1 (en) 2003-04-11 2023-08-02 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
CA2881078C (en) * 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
CN101076332A (zh) * 2004-10-13 2007-11-21 Ptc医疗公司 吡唑或三唑化合物及其用于制备治疗体细胞突变相关疾病的药物的用途
HUE031643T2 (en) 2006-04-03 2017-07-28 Technion Res & Dev Foundation New aminoglycosides and their applications in the treatment of genetic disorders
US20080090845A1 (en) 2006-08-23 2008-04-17 Neurogen Corporation Haloalkyl-substituted pyrimidinone derivatives
CN101687883B (zh) 2007-05-25 2012-05-23 沃泰克斯药物股份有限公司 囊性纤维化跨膜传导调节因子的调节剂
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2422817A1 (en) 2010-07-29 2012-02-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Flavin-nucleic acid ligand conjugates
JP5877200B2 (ja) 2010-08-05 2016-03-02 ユニヴェルシテ ドゥ ドロワ エ サンテ ドゥ リール ナンセンス突然変異による疾患の治療に有用な化合物及びその化合物を含む医薬組成物
MX363437B (es) 2012-12-13 2019-03-22 Novartis Ag Pirimido-4,5-b]-quinolina-4,5 (3h,10h)-dionas como supresoras de mutacion sin sentido.
EP3152207B1 (en) 2014-06-03 2019-05-08 Novartis AG Pyridopyrimidinedione derivatives as suppressors of non-sens mutations
CA2950724A1 (en) 2014-06-03 2015-12-10 Novartis Ag Naphthyridinedione derivatives
WO2015186062A1 (en) 2014-06-03 2015-12-10 Novartis Ag PYRIMIDO[4,5-b]QUINOLINE-4,5(3H,10H)-DIONE DERIVATIVES

Also Published As

Publication number Publication date
CN106459043B (zh) 2018-12-28
CN106459043A (zh) 2017-02-22
CA2950724A1 (en) 2015-12-10
TWI688565B (zh) 2020-03-21
PH12016502293A1 (en) 2017-02-13
BR112016027383A2 (pt) 2017-08-15
AU2018200421A1 (en) 2018-02-08
TN2016000490A1 (en) 2018-04-04
SG11201609209YA (en) 2016-12-29
EP3152209A1 (en) 2017-04-12
JP6343034B2 (ja) 2018-06-13
CL2016003081A1 (es) 2017-06-09
PE20170086A1 (es) 2017-03-17
UY36150A (es) 2016-01-29
IL248773B (en) 2019-12-31
WO2015186063A1 (en) 2015-12-10
US20150344476A1 (en) 2015-12-03
US20190248784A1 (en) 2019-08-15
JP2018138609A (ja) 2018-09-06
KR20160148679A (ko) 2016-12-26
EP3152209B1 (en) 2019-03-20
JP2017516821A (ja) 2017-06-22
CU20160182A7 (es) 2017-03-03
AP2016009545A0 (en) 2016-11-30
EA201692270A1 (ru) 2017-03-31
IL248773A0 (en) 2017-01-31
US10138232B2 (en) 2018-11-27
BR112016027383A8 (pt) 2021-07-20
AR100706A1 (es) 2016-10-26
PH12016502293B1 (en) 2017-02-13
AU2015270125A1 (en) 2016-11-24
MX2016015856A (es) 2017-04-25
CU24438B1 (es) 2019-09-04
MX374245B (es) 2025-03-05
CR20160565A (es) 2017-03-10
SV2016005331A (es) 2018-08-20
MY178379A (en) 2020-10-09
AU2015270125B2 (en) 2017-10-19
EA030374B1 (ru) 2018-07-31
ES2731802T3 (es) 2019-11-19
GT201600252A (es) 2018-12-18
TW201625610A (zh) 2016-07-16
KR101905295B1 (ko) 2018-10-05
PH12018501709A1 (en) 2019-08-14

Similar Documents

Publication Publication Date Title
BR112016026291A2 (pt) Derivados do ácido borônico e usos terapêuticos dos mesmos
CO2017001994A2 (es) Compuestos activos hacia bromodominios
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
GT201400144A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
CU20150061A7 (es) PIRIMIDO-[4,5-b]-QUINOLINA-4,5(3H,10H)-DIONAS COMO SUPRESORAS DE MUTACIÓN SIN SENTIDO
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
SV2016005331A (es) Derivados de naftiridinadiona
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
CL2016002835A1 (es) “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
MX2018005725A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer.
CR20150019A (es) Derivados de carbamato/urea
SV2017005381A (es) Compuestos de imidazopiridazina
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
CL2018001493A1 (es) Nuevos derivados de fenilo
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY35747A (es) Derivados sustituidos de fenilalanina
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio
CR20160448A (es) Nuevos derivados de piridina
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
UY34761A (es) Composiciones parasiticidas que comprenden derivados de benzimidazol, métodos y usos de los mismos.